IEC-18 cells; lysophosphatidic acid, protein kinase C downregulation; epithelial restitution; G i and G q PROTEIN KINASE C (PKC), a major target for the tumorpromoting phorbol esters, has been implicated in the signal transduction pathways that mediate a wide range of biological responses in response to growth factors, hormones, neuropeptides, and cellular oncogenes (40, 43, 53) . Molecular cloning has demonstrated the presence of multiple related PKC isoforms including conventional PKCs (␣, ␤ 1 , ␤ 2 , and ␥), novel PKCs (␦, ⑀, , and ), and atypical PKCs ( and ), all of which possess a highly conserved catalytic domain (35, 41, 43) . The different PKC isoforms exhibit distinct patterns of expression in different cell types and tissues as well as distinct subcellular distributions, leading to the view that they play distinct, rather than redundant, roles in signal transduction (52) .
The sequential proliferation, lineage-specific differentiation, migration, and cell death of the epithelial cells of the intestinal mucosa are a tightly regulated process that is modulated by a broad spectrum of regulatory peptides (8, 27, 55) . The signaling mechanisms involved, however, remain incompletely understood. The PKC family has been implicated in the regulation of multiple important functions in intestinal epithelial cells including differentiation (65) , proliferation (1, 14, 68) , migration (4), apoptosis (68) , and carcinogenesis (9, 28, 46, 56) . It is known that intestinal epithelial cells express multiple isoforms of the PKC family, including ␣, ␤, ␦, ⑀, and . These cells have emerged as an important model system to elucidate isoform-specific PKC signaling. Mice with transgenic overexpression of PKC␤ 2 in the intestinal epithelium exhibit hyperproliferation of the colonic epithelium and an increased susceptibility to azoxymethane-induced preneoplastic lesions in the colon (39) . PKC⑀ has been shown to act as an oncogene when overexpressed in intestinal epithelial cells (46) . PKC also has been implicated in the downregulation of the tumor suppressor gene Cdx-2 by oncogenic Ras in vivo (30) . Furthermore, loss of PKC␣ expression in sporadic human and chemically induced colonic cancers may confer a relative growth advantage during colonic malignant transformation (56) . Despite these findings indicating a critical role for PKCs in intestinal epithelial cell proliferation and carcinogenesis, little is known about the mechanisms of PKC signaling in these cells. In particular, downstream signaling targets for PKCs in epithelial cells remain poorly characterized.
Protein kinase D (PKD; also known as PKC) is a serine/threonine protein kinase with distinct structural features and unique enzymological properties (26, 61) . In particular, the catalytic domain of PKD shows very low homology to the conserved kinase subdomain of the PKCs and displays a distinct substrate specificity (42, 61, 64) . In contrast to all known PKCs, the NH 2 -terminal region of PKD contains a pleckstrin homology (PH) domain that regulates enzyme activity (22) and lacks a sequence with homology to a typical PKC autoinhibitory pseudosubstrate motif (61) . However, the amino-terminal region of PKD contains a tandem repeat of cysteine-rich, zinc finger-like motifs that binds phorbol esters with high affinity (21, 61) and mediates PKD translocation to the cell membrane (32) . PKD/PKC can be activated in vitro by diacylglycerol (DAG)/phorbol esters in the presence of phosphatidyl-L-serine (10, 64, 74) , indicating that PKD/PKC is a phorbol ester/DAG-stimulated protein kinase (54) .
More recently, a second mechanism of PKD activation has been identified that involves PKD phosphorylation (23, 34, 66, 74) . Specifically, treatment of intact fibroblasts with biologically active phorbol esters (74) , bryostatin (33) , growth factors, and G protein-coupled receptor (GPCR) agonists (45, 63, 75) induces PKD activation that persists during cell disruption and immunoprecipitation. Treatment with PKC-selective inhibitors prevents PKD activation by all these factors (33, 54, 74, 75) . Furthermore, cotransfection of PKD with constitutively active mutants of PKC⑀ and PKC dramatically increased the catalytic activity of PKD (67, 74) and led to complex formation between PKD and PKC (67) . These findings revealed a link between PKCs and PKD and implied that PKD lies downstream of PKCs in a novel signal transduction network (54, 66) .
Nontransformed IEC-6 and IEC-18 cells, derived from fetal rat intestinal crypt cells (48) , have provided an in vitro model with which to examine intestinal epithelial cell migration, differentiation, and proliferation (11, 16, 49, 55) . To further elucidate PKC-mediated signaling in epithelial cells, we examined whether PKD is endogenously expressed and regulated via PKC in IEC-6 and IEC-18 cells. Our results demonstrate that treatment of these cells with the biologically active phorbol ester phorbol 12,13-dibutyrate (PDBu) induces a striking increase in PKD activity but, unlike classic and novel PKCs, does not deplete PKD in these cells. Lysophosphatidic acid (LPA) and angiotensin that signal through heptahelical receptors coupled to heterotrimeric G proteins also promote a rapid PKCdependent PKD activation in IEC-6 and IEC-18 cells. Although LPA and angiotensin receptors are thought to couple to G q (37, 38, 51) and thereby to phospholipase C (PLC) (13) in fibroblasts, prior treatment of IEC-6 cells with pertussis toxin (PTx), which inactivates G i , selectively attenuated PKD activation by LPA. Our results identify PKD activation as a novel early point of convergence and integration of G i and G q signaling in intestinal epithelial cells.
MATERIALS AND METHODS
Cell culture. IEC-6 and IEC-18 cells were purchased from American Type Culture Collection. Stock cultures of these cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal bovine serum (FBS) in a humidified atmosphere containing 10% CO 2 -90% air at 37°C. For experimental purposes, cells were plated in 100-mm dishes at 3 ϫ 10 5 cells/dish in DMEM containing 5% FBS, grown to near confluency (5-7 days), and then changed to serum-free DMEM for 18-24 h before the experiment.
Immunoprecipitation. Cultures of IEC-6 cells, treated as described in the individual experiments, were washed and lysed in 50 mM Tris ⅐ HCl, pH 7.6, 2 mM EGTA, 2 mM EDTA, 1 mM dithiothreitol (DTT), 10 g/ml aprotinin, 10 g/ml leupeptin, 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride, and 1% Triton X-100 (lysis buffer A). Cell lysates were clarified by centrifugation at 15,000 g for 10 min at 4°C. PKD was immunoprecipitated at 4°C for 2-4 h with the PA-1 antiserum (1:100), as previously described (74) . The immune complexes were recovered with the use of protein A coupled to agarose.
Kinase assay of PKD. PKD autophosphorylation was determined in an in vitro kinase assay by mixing 20 l of PKD immunocomplexes with 10 l of a phosphorylation mixture containing (final concentration) 100 M [␥- 32 P]ATP (specific activity 400-600 cpm/pmol), 30 mM Tris ⅐ HCl, pH 7.4, 10 mM MgCl 2 , and 1 mM DTT. After 10 min of incubation at 30°C, the reaction was stopped by washing with 200 l of kinase buffer and then adding an equal volume of 2ϫ SDS-PAGE sample buffer (200 mM Tris ⅐ HCl, pH 6.8, 2 mM EDTA, 0.1 M Na 3 VO 4 , 6% SDS, 10% glycerol, and 4% 2-mercaptoethanol), followed by SDS-PAGE analysis (64, 74) . The gels were dried, and the 110-kDa radioactive band corresponding to autophosphorylated PKD was visualized by autoradiography. Autoradiographs were scanned in a GS-710 Calibrated Imaging Densitometer (Bio-Rad), and the labeled band was quantified with the Quantity One software program.
Exogenous substrate phosphorylation by immunoprecipitated PKD was carried out by mixing 20 l of the washed immunocomplexes with 20 l of a phosphorylation mixture containing 2.5 mg/ml syntide-2 (PLARTLSVAGLPGKK), a peptide based on phosphorylation site two of glycogen synthase. After 10 min of incubation at 30°C, the reaction was stopped by adding 100 l of 75 mM H 3 PO 4 and spotting 75 l of the supernatant on P-81 phosphocellulose paper. Free [␥-32 P]ATP was separated from the labeled substrate by washing the P-81 paper four times for 5 min in 75 mM H 3 PO 4 . The papers were dried, and the radioactivity incorporated into syntide-2 was determined by Cerenkov counting.
Western blot analysis. Quiescent cultures of either IEC-6 or IEC-18 cells grown on 100-mm dishes were washed twice with DMEM and then treated as described in the individual experiments. The cells were lysed in 2ϫ SDS-PAGE sample buffer. After SDS-PAGE was carried out on 8% gels, proteins were transferred to Immobilon-P membranes (Millipore) and blocked by 3-6 h of incubation with 5% nonfat milk in phosphate-buffered saline, pH 7.2. Membranes were then incubated overnight with an antiserum that specifically recognizes the phosphorylated state of serine 916 of PKD (pS916) at a dilution of 1:500 or with antibodies that specifically recognize the different PKC isoforms at a dilution of 1 g/ml in phosphate-buffered saline containing 5% nonfat dried milk. Horseradish peroxidase-conjugated anti-rabbit IgG antibody (1:5,000; Amersham) was then applied for 1 h at room temperature after three washes with PBS containing 0.05% Tween. Immunoreactive bands were detected by Western blotting with ECL (enhanced chemiluminescence) reagents (Amersham). 
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where R, R min , and R max are the ratios of the emission at 510 nm following excitation at 340 and 380 nm, F max is the fluorescence after the addition of 40 M digitonin, and F min is the fluorescence after the Ca 2ϩ in the solution has been chelated with 10-20 mM EGTA. The value of the dissociation constant (K d ) used was 224 nM.
Materials. [␥-32 P]ATP (370 MBq/ml) was from Amersham International. Bisindolylmaleimide I (GF-I), Ro-31-8220, and PTx were purchased from Calbiochem. Angiotensin II, LPA, PDBu, wortmannin, rapamycin, PD-098059, and genistein were purchased from Sigma. Protein A-agarose was from Boehringer Mannheim. PA-1 antiserum was raised against the synthetic peptide EEREMKALSERVSIL that corresponds to the carboxy-terminal region of the predicted amino acid sequence of PKD, as previously described (64, 74 ). Antibodies (PKD C-20, PKC C-20, PKC⑀ C-15, PKC C-15, PKC␦, and PKC␣ C-15) used in Western blot analysis were obtained from Santa Cruz Biotechnologies (Palo Alto, CA). An antiserum that specifically recognizes pS916 was generously provided by Dr. Doreen Cantrell (Imperial Cancer Research Institute, London, UK). Other items were from standard suppliers or as indicated in the text.
RESULTS
Expression of PKD in rat intestinal epithelial cell lines. As a first step toward defining the regulation of PKD in epithelial cells, lysates from the rat intestinal epithelial cell line IEC-6 were analyzed for the presence of PKD by Western blotting with the use of a specific antibody that recognizes the COOH-terminal region of this enzyme. A major immunoreactive band of 110 kDa, which corresponds to the molecular mass of PKD (61) , was detected in lysates of this cell line (Fig.  1A, left) . In some experiments, we noticed that PKD isolated from IEC-6 cells migrated in SDS-PAGE gels as a doublet. The detection of this (doublet) band was completely blocked when the immunoblots were incubated with the antibody in the presence of the synthetic peptide EEREMKALSERVSIL, which corresponds to the COOH-terminal region of the predicted amino acid sequence of PKD.
A prominent PKD band was also obtained when lysates from the same intestinal epithelial cell lines were immunoprecipitated with the PA-1 antiserum (see MATERIALS AND METHODS), and the immunoprecipitates were analyzed by Western blotting with the use of a different antibody directed against PKD (Fig. 1A,  right) . Detection of the 110-kDa band was blocked by the inclusion of the immunizing peptide during the immunoprecipitation (Fig. 1A) . These results demonstrate the expression of PKD in IEC-6 cells.
PDBu induces PKD activation in IEC-6 cells. To determine whether biologically active phorbol esters can induce PKD activation in intact IEC-6 cells, we treated cultures of these cells with PDBu for increasing times, lysed the cells, and immunoprecipitated PKD with PA-1 antiserum. The resulting immunocomplexes were incubated with [␥-32 P]ATP, and the incorporation of 32 P into PKD was analyzed by SDS-PAGE and autoradiography. As shown in Fig. 1B , PKD isolated from unstimulated IEC-6 cells had low catalytic activity. Treatment of IEC-6 cells with PDBu induced a rapid and striking increase in PKD kinase activity that was maintained during cell lysis and immunoprecipitation. PKD activation was detectable within 1 min and reached a maximum (ϳ10-fold) after 10 min of PDBu stimulation. These results demonstrate that PKD activation is one of the early events induced by phorbol esters in epithelial cells.
Recently, an antiserum specifically recognizing the phosphorylated form of a PKD COOH-terminal resi- . The immunoprecipitates were analyzed by Western blotting using the PA-1 antiserum as described in MATERIALS AND METHODS. B: PKD activation in IEC-6 cells. Confluent and quiescent cultures of IEC-6 cells were treated for various times with 100 nM PDBu at 37°C as indicated. Cultures were lysed with lysis buffer A and immunoprecipitated with PA-1 antiserum, and PKD activity in the immunocomplexes was determined by an in vitro kinase (IVK) assay as described in MATERIALS AND METHODS, followed by SDS-PAGE and autoradiography. Identical experiments were done in parallel where Western blot analysis was performed on cells lysed with 2ϫ sample buffer by using an antibody raised against the phosphorylated state of serine 916 (pS916). Inset: representative autoradiogram of IVK assay and pS916 Western blots. The level of PKD autophosphorylation in the IVK experiments was quantified by scanning densitometry. The results, expressed as percentages of the maximum increase in phosphorylation, are means Ϯ SE (n ϭ 3) plotted as a function of time.
due, serine 916, was developed and used to detect in vivo autophosphorylation at this site by active PKD (34) . Thus the pS916 antiserum provides a novel approach for detecting conversion of PKD to an active form within cells. Here, lysates from IEC-6 cells stimulated with PDBu for various times were analyzed by SDS-PAGE, followed by Western blot analysis with the pS916 antiserum. PDBu stimulation induced a dramatic increase in the immunoreactivity of the PKD band indicative of phosphorylation at serine 916 (Fig.  1B, inset ). An increase in PKD autophosphorylation was detectable within 1 min and reached a maximum (ϳ10-fold) after 5-10 min of PDBu stimulation.
Stimulation of intact IEC-6 cells with increasing concentrations of PDBu for 10 min induced a striking dose-dependent increase in PKD activation, as judged by assays of in vitro PKD kinase activity after immunoprecipitation or by Western blotting with pS916 antibody to detect PKD autophosphorylation in intact cells ( Fig. 2A) . Half-maximal PKD activation by PDBu was achieved at 10-25 nM (Fig. 2B) .
As an independent measure of PKD activation induced by PDBu in IEC-6 cells, we also examined phosphorylation of an exogenous substrate using syntide-2 (29, 36), a peptide identified as an excellent model substrate for PKD (42, 61, 64, 67) . Consistent with the results of autophosphorylation assays, syntide-2 phosphorylation assays also showed that IEC-6 cells stimulated with PDBu had dramatically increased PKD activity (Fig. 2B, inset) . Together, the results presented in Figs. 1 and 2 provide multiple lines of evidence indicating that exposure of intact IEC-6 cells to PDBu induces rapid and striking PKD activation.
We also determined the role of PKCs in PKD activation induced by PDBu. Cultures of IEC-6 cells were treated with various concentrations of either Ro-31-8220 or GF-I, selective inhibitors of phorbol estersensitive isoforms of PKC (31, 60, 72) but not PKD (33, Fig. 2 . PDBu activates PKD in a dose-dependent and protein kinase C (PKC)-dependent manner. A: PDBu activates PKD in a dose-dependent manner. Top: confluent and quiescent cultures of IEC-6 cells in IVK experiments were treated with various concentrations of PDBu for 10 min at 37°C as indicated. The cultures were lysed in lysis buffer A and immunoprecipitated with PA-1 antiserum, and PKD activity was determined by an IVK assay as described in MATERIAL AND METHODS. The autoradiogram shown is representative of 3 independent experiments. Bottom: identical experiments were carried out in parallel cultures where Western blot analysis with pS916 antiserum was performed following lysis of the cells with 2ϫ sample buffer as described in MATERIALS AND METHODS. The Western blot shown is representative of 3 independent experiments. B: scanning densitometry. The results shown are means Ϯ SE (n ϭ 3) of the level of PKD activation from IVK obtained from scanning densitometry and are expressed as percentages of the maximum increase in phosphorylation obtained with 100 nM PDBu. Inset: confluent and quiescent cultures of IEC-6 cells were either kept in serum-free DMEM (Ϫ) or treated with 100 nM PDBu for 10 min at 37°C. After lysis with lysis buffer A and immunoprecipitation with PA-1 antibody, PKD activity in the immunocomplexes was then measured by syntide-2 phosphorylation, as described in MATERIALS AND METHODS. C: Ro-31-8220 (Ro) and bisindolylmaleimide I (GF-I) inhibit PKD activity. Confluent and quiescent IEC-6 cells were incubated for 1 h with different concentrations of the PKC inhibitors Ro or GF-I. The cultures were subsequently stimulated for 10 min with 100 nM PDBu at 37°C. Cells were lysed with lysis buffer A and immunoprecipitated with PA-1 antiserum, and PKD activity was determined by an IVK assay as described in 74, 75) , before PDBu stimulation. As shown in Fig. 2C , the increase in PKD activity induced by PDBu was prevented by treatment with either Ro-31-8220 or GF-I. These findings imply that PDBu activates PKD in IEC-6 cells through a PKC-dependent pathway.
Long-term exposure to PDBu downregulates PKCs but not PKD. We next examined the effect of long-term treatment with PDBu on the level and serine 916 phosphorylation of PKD from IEC-6 cells. As shown in Fig. 3 , Western blotting with a PKD antibody revealed that exposure to PDBu induced a marked electrophoretic retardation of PKD that was evident 0.5 and 2 h after addition of PDBu. The apparent decrease of PKD at these times is the result of decreased detectability of phosphorylated PKD at serine 916 (34, 50) . In agreement with this explanation, the decrease of both electrophoretic mobility and detectability coincided temporally with a striking increase in serine 916 phosphorylation (Fig. 3) .
Interestingly, continued exposure to PDBu did not lead to downregulation of PKD in IEC-6 cells. In contrast, serine 916 phosphorylation, indicative of PKD activity, declined gradually over the 24-h period. A plausible interpretation of this decline is that continuous exposure to PDBu induced the depletion of PKC isoforms that are required for PKD activation and autophosphorylation at serine 916. To test this possibility, we analyzed the lysates from IEC-6 cells incubated with PDBu for various times for the presence of PKCs ␣, ␦, ⑀, and . As shown in Fig. 3 , treatment with PDBu induced a dramatic downregulation of PKCs ␣, ␦, and ⑀ that was apparent by 6 h and extensive at 24 h. These findings indicate that, in contrast to classic and novel PKCs, PKD does not undergo downregulation upon chronic treatment with PDBu. The reversal in the phosphorylation of serine 916, indicative of PKD activity, correlated with the downregulation of the classic and novel PKCs and supports the hypothesis that one or more of these PKCs are required for PDBu-induced PKD activation.
To confirm the requirement of PKC in mediating PDBu-induced PKD activation, we treated IEC-6 cells with PDBu for 24 h to produce extensive depletion of classic and novel PKCs and then challenged with PDBu for 10 min. As shown in Fig. 3B , the increase in PKD activity induced by acute exposure to PDBu was abrogated by prior treatment with this PKC agonist for 24 h. The results shown in Fig. 3 provide additional evidence indicating that PKC(s) is required for PKD activation and demonstrate that prolonged exposure to PDBu induces differential depletion of PKCs but not PKD.
LPA induces PKD activation in IEC-6 cells. Next, we determined whether PKD is regulated in IEC-6 cells through receptor-mediated pathways. Recently, LPA, a major bioactive lipid of serum (12) , was implicated in intestinal epithelial wound healing by modulation of intestinal epithelial cell migration and proliferation in the IEC-6 cell model (59) . LPA activates several signaling pathways via heptahelical receptors linked to G q , G i , and G 12 , including PLC-mediated hydrolysis of membrane phosphoinositides leading to the generation of the second messengers inositol 1,4,5-trisphosphate, which stimulates Ca 2ϩ mobilization from intracellular stores, and DAG, which activates classic and novel PKCs (15, 17, 37) . Here we examined whether LPA can stimulate PKD activation in intact IEC-6 cells.
Treatment of IEC-6 cells with increasing concentrations of LPA induced a striking increase in PKD activity and serine 916 phosphorylation in a concentrationdependent manner (Fig. 4A) . Half-maximal and maximal PKD activation was achieved at 0.1 and 1 M LPA, respectively (Fig. 4B) . Consistent with these results, syntide-2 phosphorylation assays also demonstrated that LPA induces a marked increase in PKD activity in IEC-6 cells (Fig. 4B, inset) .
PKD activation was a rapid consequence of the addition of LPA to IEC-6 cells (Fig. 4C) . A marked increase in PKD activity was evident at as early as 30 s of LPA stimulation. These results indicate that LPA induces rapid PKD activation at concentrations that are present physiologically in serum.
LPA stimulates PKD activation via PKC. To determine the role of PKCs in PKD activation induced by M) that abrogated LPA-induced PKD activation in intact IEC-6 cells, did not inhibit PKD activity. Similar results were obtained when the PKC inhibitor GF-I was used instead of Ro-31-8220 (results not shown). These results imply that Ro-31-8220 and GF-I do not inhibit PKD activity directly but interfere with LPAmediated PKD activation in intact cells by blocking PKC. Furthermore, depletion of PKCs by treatment with PDBu for 24 h abrogated LPA-induced PKD activation. (Fig. 5B) .
In contrast to the results obtained with PKC inhibitors, either treatment with the protein tyrosine kinase inhibitor genistein, which prevents LPA-mediated Ras activation (20, 62) , the MEK inhibitor PD-098059 (2), which prevents extracellular signal-regulated kinase activation, and the phosphatidylinositol 3-kinase inhibitors LY-294002 and wortmannin (44, 71) or interference with activation of the phosphatidylinositol 3-kinase downstream target p70 ribosomal S6 kinase (p70 S6K ) with rapamycin (18, 69, 70) did not affect PKD activation in response to LPA in IEC-6 cells (Fig. 5C ). The results presented in Fig. 5 indicate that LPA induces PKD activation through PKC in IEC-6 cells.
LPA stimulates PKD activation via a PTx-sensitive pathway. LPA binds to a seven-transmembrane domain receptor(s) that couples to G q , G i , and G 12 signaling (17, 38) . To clarify the G protein pathways leading to LPA-induced PKD activation, we examined the effect of treatment with PTx, which catalyzes ADP ribosylation and inactivation of G proteins of the G i /G o family. As shown in Fig. 6 , exposure of IEC-6 cells to increasing concentrations of PTx for 3 h completely blocked the increase in PKD activity induced by subsequent LPA stimulation in a concentration-dependent manner. Half-maximal and maximal inhibition of LPAinduced PKD activation was achieved at ϳ1 and 10 ng/ml PTx, respectively. In contrast, exposure of parallel cultures to 100 ng/ml PTx for 3 h did not interfere with PKD activation induced by PDBu, which directly activates PKC and bypasses receptor-mediated pathways (results not shown). These results indicate that LPA-stimulated PKD activation is mediated through G i in IEC-6 cells.
It is known that the ␤␥-subunits rather than ␣-subunits of heterotrimeric G i proteins preferentially activate the ␤-isoforms of PLC (13, 51) . The LPA receptor http://ajpcell.physiology.org/ subtype EDG-2 induces a rapid PLC-dependent increase in the cytoplasmic Ca 2ϩ concentration via a PTx-sensitive G i pathway (3), whereas the other LPA receptor subtypes (e.g., EDG-4 and EDG-7) induce Ca 2ϩ fluxes via PTx-insensitive G q (3, 6) . The rapid and transient increase in the cytoplasmic Ca 2ϩ concentration induced by LPA in IEC-6 cells was strikingly reduced (ϳ80%) by prior treatment of the cells with PTx (Fig. 6, inset) . These findings indicate that LPA induces Ca 2ϩ mobilization, like PKD activation, via G i in IEC-6 cells and suggest the involvement of the EDG-2 receptor in the action of LPA in these cells.
Angiotensin induces PKD activation in IEC-6 cells via PKC. In fibroblasts, PKD is rapidly activated by peptide agonists that signal through heptahelical receptors coupled to G q (73, 75) . Recent results indicate that G␣ q activation is sufficient to stimulate sustained PKD activation via PKC and show that the endogenous G␣ q mediates PKD activation in response to acute bombesin receptor stimulation (73) . Previous reports indicated that IEC-6 cells endogenously express the AT 1 subtype of angiotensin receptor, which signals via G q (57, 58) . We verified that addition of angiotensin (5-50 nM) to IEC-6 cells induced a PTx-insensitive increase in cytosolic Ca 2ϩ concentration (Fig. 6, inset) . Here, we examined whether angiotensin stimulates PKD activation in these epithelial intestinal cells.
Stimulation of intact IEC-6 cells with increasing concentrations of angiotensin for 90 s induced a striking, dose-dependent increase in PKD activation, as judged by assays of in vitro PKD kinase activity after immunoprecipitation with PA-1 antiserum or Western blotting of cell lysates with pS916 antibody to detect PKD autophosphorylation (at serine 916) in intact cells (Fig. 7A) . Half-maximal and maximal PKD activation by angiotensin was achieved at 2 and 10 nM, respectively (Fig. 7B, left) . In addition, syntide-2 phosphorylation assays also demonstrated that angiotensin induced a marked increase in PKD activity in IEC-6 cells (Fig. 7B, inset) .
Treatment of IEC-6 cells with angiotensin induced a very rapid increase in PKD activation, which was detectable as early as 15 s after agonist stimulation and reached maximal stimulation within 1 min, as shown by in vitro kinase assays after immunoprecipitation or by Western blotting with the pS916 antibody (Fig. 7, A  and B) . Treatment of IEC-6 cells with either GF-I or Ro-31-8220 potently blocked PKD activation induced by subsequent addition of angiotensin in a concentrationdependent fashion. In contrast, GF-I or Ro-31-8220 did not inhibit PKD activity when added directly to the in vitro kinase assay, even at concentrations (0.25-1 M) that prevented angiotensin-mediated PKD activation in intact IEC-6 cells (Fig. 8, A and B) . Exposure of IEC-6 cells to other kinase inhibitors including genistein, PD-098059, wortmannin, or rapamycin did not affect PKD activation in response to angiotensin (results not shown). In addition, depletion of PKCs by prolonged exposure to PDBu abrogated angiotensininduced PKD activation (Fig. 8C) . Thus angiotensin, like LPA, induces PKD activation in intact IEC-6 epithelial cells via PKC.
PKD activation integrates G i and G q signaling pathways in IEC-6 cells. To determine the effect of PTx on PKD activation induced by angiotensin in IEC-6 cells, we treated cultures of these cells with 100 ng/ml PTx for 3 h and then challenged with either angiotensin or LPA for 10 min. PKD activity was determined by in vitro kinase assays after immunoprecipitation, Western blotting with the pS916 antibody, and syntide-2 phosphorylation assays (Fig. 9 ). In agreement with the results presented in Fig. 6 , treatment with PTx profoundly inhibited the activation and the serine 916 phosphorylation of PKD induced by LPA. In contrast, angiotensin-induced PKD activation was not affected by an identical PTx treatment, as assessed by all the assays used. These results imply that angiotensin signals PKD activation via G q and indicate that PKD integrates pathways mediated by G i -and G q -linked receptors in epithelial cells.
PKD activation by PDBu, LPA, and angiotensin in IEC-18 cells. To substantiate the findings obtained with IEC-6 cells, we also examined PKD expression and regulation in IEC-18 cells, a different crypt intestinal cell line derived from rat ileal epithelium (48) . Initially, we confirmed that PKD is expressed in IEC-18 cells, as judged by Western blot analysis of either cell lysates or PA-1 immunoprecipitates (Fig.   Fig. 8 . ANG II induces PKD activation through a PKC-dependent pathway. A: Ro and GF-I inhibit PKD activity. Confluent IEC-6 cells were incubated for 1 h with different concentrations of the PKC inhibitor GF-I (top left) or Ro (top right). Control cells (Ϫ) received equivalent amounts of solvent. The cultures were subsequently stimulated for 90 s with 100 nM ANG II at 37°C. Cells were lysed with lysis buffer A and immunoprecipitated with PA-1 antiserum. PKD activity was then determined by an IVK assay, as described in MATERIALS AND METHODS. Parallel cultures were treated with 100 nM ANG II for 90s at 37°C. Cells were lysed with lysis buffer A and immunoprecipitated with PA-1 antiserum. PKD activity was then determined by an IVK assay in absence or presence of the indicated concentrations of GF-I (bottom left) or Ro (bottom right) added to the incubation mixture. B: scanning densitometry. The results shown are means Ϯ SE (n ϭ 3) of the level of PKD activation obtained from scanning densitometry and are expressed as percentages of the maximum increase in phosphorylation obtained from cells incubated with 100 nM ANG II for 90 s at 37°C. F, values corresponding to PKD activity from cells incubated with GF-I (left) or Ro (right); ‚, values corresponding to PKD activity determined by an IVK assay in the absence or presence of indicated concentrations of GF-I (left) or Ro (right) added to the incubation mixture. C: PKD activity after prolonged PDBu treatment. Confluent and quiescent cultures of IEC-6 cells were treated for 24 h either without (Ϫ) or with (ϩ) 200 nM PDBu at 37°C and washed with serum-free DMEM. After 30 min at 37°C in serum-free media, these cells were then incubated for a further 90 s either without or with 100 nM ANG II as indicated. The cells were then lysed with lysis buffer A and immunoprecipitated with PA-1 antiserum. PKD activity was determined by an IVK assay, as described in MATERIALS AND METHODS, followed by SDS-PAGE and autoradiography.
10A). Next, we examined the effect of PDBu on PKD expression and regulation.
Treatment of IEC-18 cells with PDBu induced a striking and transient increase in the phosphorylation of serine 916 and electrophoretic retardation of endogenously expressed PKD but did not reduce the level of PKD (Fig. 10B ). An identical long-term treatment with PDBu depleted the conventional PKC␣ and novel PKCs ␦ and ⑀ but not atypical PKC, which is known to be unresponsive to phorbol esters. The results shown in Fig. 10 with IEC-18 cells are in very good agreement with those shown in Fig. 3 with IEC-6 cells and confirm that PKD is activated but not depleted by long-term treatment with PDBu.
We also determined the time course and dose response of PKD activation in response to PDBu, LPA, and angiotensin. Lysates of IEC-18 cells treated with 100 nM PDBu, 5 M LPA, or 100 nM angiotensin for various times or with increasing concentrations of these agonists for a fixed time were analyzed by Western blotting with the pS916 antibody to detect PKD autophosphorylation at serine 916. Stimulation of IEC-18 cells with these agonists induced PKD phosphorylation in a dose-and time-dependent fashion (Fig. 11, A-C) . In other experiments, we verified that exposure to PDBu, LPA, and angiotensin induced striking PKD activation using syntide-2 phosphorylation assays (results not shown). Treatment of IEC-18 cells with PTx (100 ng/ml for 3 h) attenuated PKD autophosphorylation at S916 induced by LPA but did not interfere with the stimulatory effect of either PDBu or angiotensin (Fig. 11D) . These results with IEC-18 cells substantiate the notion that PKD activation is a novel early molecular event in the response of epithelial cells to activation of G i -and G q -coupled receptors.
DISCUSSION
The PKC family plays a central role in the signal transduction pathways that mediate important functions in intestinal epithelial cells including differentiation (65), proliferation (1, 14) , migration (4), and carcinogenesis (46) . The present challenge is to identify downstream targets for PKCs that transmit signals to the cell interior and participate in the regulation of processes that control intestinal epithelial cell function.
PKD is a novel serine/threonine protein kinase that can be distinguished from PKC isoforms by a variety of criteria including catalytic domain structure, substrate specificity, the presence of a PH domain, and absence of a pseudosubstrate autoinhibitory motif, which is present in all known PKCs upstream of the first cysteine-rich domain (54) . PKD has been implicated in the regulation of endothelial growth factor receptor signaling (5), Na ϩ /H ϩ antiport activity (19) , Golgi organization and function (24, 47) , nuclear factor-B-mediated gene expression (25) , and cell migration (7) . As a first step to elucidate the mechanism of activation of PKD in intestinal epithelial cells, we examined the regulation of this enzyme in IEC-6 and IEC-18 cells, derived from fetal rat intestinal crypt cells. These cells have provided an in vitro model to examine intestinal epithelial cell migration, restitution, and proliferation (11, 16, 49, 55) .
Our results demonstrate that treatment of intact IEC-6 cells with the tumor-promoting phorbol ester PDBu induces rapid PKD activation. The conversion of PKD into this activated state occurs within minutes of phorbol ester stimulation of intact IEC-6 cells and, thus, is one of the early events induced by phorbol esters in these cells.
It is well established that long-term exposure to biologically active phorbol esters induces downregulation of conventional and novel PKC isoforms in mammalian cells. Binding of phorbol esters to these PKCs is mediated by a tandem repeat of cysteine-rich motifs, the C1 region, and is associated with their translocation to cellular membranes (52) . Interestingly, PKD also possesses a tandem repeat of cysteine-rich motifs (21, 26, 61) and is translocated to the plasma membrane in response to phorbol ester stimulation (32) . However, little is known about the regulation of PKD level in response to long-term treatment with phorbol esters. The results presented here indicate that, in contrast to classic and conventional PKCs, prolonged exposure to PDBu did not induce downregulation of PKD protein under conditions that produced striking depletion of PKCs ␣, ␦, and ⑀. These results, corroborated in IEC-6 and IEC-18 cells, identify another important functional difference between PKD and phorbol ester-sensitive isoforms of PKC.
To investigate the physiological significance of the PKC/PKD pathway in intestinal epithelial cells, we examined PKD regulation in these cells via receptormediated pathways. LPA, a major bioactive lipid of serum, has been shown to elicit a broad spectrum of biological responses in many cell types (15, 17, 37) . LPA binds to seven-transmembrane domain receptor(s) and activates several heterotrimeric G proteins including G q , G i , and G 12 , which are responsible for transducing LPA signals into multiple biological responses (17, 38) . In this study, we report that LPA stimulation promotes a rapid and concentration-dependent PKD activation in intact IEC-6 cells through a PKC-dependent pathway.
In fibroblasts, LPA-induced PKC activation is thought to be mediated by LPA receptor coupling to PTx-insensitive G q (37) . In contrast, our results with IEC-6 cells demonstrate that PKC-dependent PKD activation induced by LPA was attenuated markedly and selectively by prior treatment of these cells with low concentrations of PTx. These results identify a novel PTx-sensitive molecular response in the action of LPA and demonstrate, for the first time, the involvement of a G i -dependent pathway leading to PKD activation in epithelial cells. It is known that the ␤␥-subunits, rather than ␣-subunits, of heterotrimeric G i proteins preferentially activate the ␤ 2 and ␤ 3 isoforms of PLC (13, 51) . Unlike PLC-␤ 2 , which is expressed only in certain cells of hematopoietic origin, PLC-␤ 3 is widely distributed (13, 51) . Recently, the LPA receptor subtype EDG-2 has been shown to induce a rapid PLC-dependent increase in the cytoplasmic Ca 2ϩ concentration via PTx-sensitive G i (3) , whereas the other LPA receptor subtypes cloned so far (e.g., EDG-4 and EDG-7) induce Ca 2ϩ fluxes via PTx-insensitive G q (3, 6 ). Here we found that treatment of IEC-6 cells with PTx markedly attenuated Ca 2ϩ mobilization in response to LPA. Our results, therefore, are consistent with a model in which LPA induces PKC-dependent, PTx-sensitive PKD activation via a pathway involving EDG-2 and G i in IEC-6 cells.
Recent results with transfected COS-7 cells indicate that G␣ q activation is sufficient to stimulate sustained PKD activation via PKC and show that the endogenous G␣ q mediates PKD activation in response to acute bombesin receptor stimulation (73) . Here we have shown that addition of angiotensin to IEC-6 cells induced a very rapid activation of endogenous PKD that was prevented by inhibitors of PKC. In contrast to the results obtained with LPA, treatment of IEC-6 cells with PTx did not affect PKD activation in response to angiotensin. These results demonstrate that inhibition of LPA-induced PKD activation by PTx is selective and suggest that angiotensin induces PKD activation via G q in IEC-6 cells. Thus PKD is activated in intestinal epithelial cells by agonist stimulation of GPCRs that signal via G i and G q . PKD activation is accompanied by an increase in its phosphorylation at multiple sites (23, 34, 66) . Previous work has used the site-specific phosphopeptide antibody approach to identify a phosphorylation site within the COOH-terminal region of PKD at serine residue 916 (34) . Mutational analysis has indicated that serine 916 is an in vivo autophosphorylation site for active PKD. Using the pS916 antibody, we have shown here a striking increase in the phosphorylation of serine 916 of endogenous PKD in response to both pharmacological (phorbol ester) and physiological (LPA, angiotensin) stimulation of IEC-6 and IEC-18 cells.
Recently, LPA has been shown to stimulate intestinal epithelial wound healing by enhancing intestinal epithelial cell migration in the IEC-6 cell model as well as in vivo (59) . LPA induced IEC-6 cell migration, like PKD activation, through a PTx-sensitive pathway. Other studies have indicated that PKCs play a role in intestinal epithelial cell motility (4), and PKD has been implicated in cell migration and metastasis in breast cancer cells via its molecular association with the cytoskeletal proteins paxillin and cortactin (7) . Recently, we found that PKD extracted from either IEC-6 or IEC-18 cells coimmunoprecipitates with paxillin and that treatment of these cells with angiotensin or PDBu stimulated cell migration (unpublished observations). Thus an attractive possibility is that PKD contributes to intestinal epithelial cell migration and wound healing, a proposition that warrants further experimental work.
In conclusion, our findings indicate that PKD is activated in intact IEC-6 cells by biologically active phorbol esters, LPA, and angiotensin through a PKCdependent signal transduction pathway. Our results, showing that PKD can function downstream of PKC in intestinal epithelial cells, raise the possibility that PKD mediates some of the biological responses elicited by PKC in these cells. Unlike conventional and novel PKCs, PKD does not undergo downregulation in response to prolonged (24 h) exposure to PDBu. LPA induced PKD activation through a PTx-sensitive pathway involving G i , whereas angiotensin promoted PKD activation via PTx-insensitive G q . The salient features of the results obtained with IEC-6 cells were corroborated with IEC-18 cells. We propose that PKD constitutes an early molecular point of convergence and integration of G i and G q signaling in intestinal epithelial cells.
